PepGen PEPG
PepGen reported a $19.39 million net loss for Q3 2026
PepGen (PEPG) filed a 10-Q with the SEC on Nov 10, 2026, 7:06 am ET. Source: the filing on SEC EDGAR.
Quarterly report, 4 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-454407
- Net loss of $19.39 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.28 for the three months ended Sep 30, 2026
- Cash and equivalents of $21.96 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
4 new risk factors · 2 removed · 1 new legal mention
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$20.38M | −$18.94M | −7.6% |
| Net income | −$19.39M | −$17.81M | −8.9% |
| Operating cash flow | −$13.18M | −$15.81M | +17% |
| Cash | $21.96M | $22.76M | −3.5% |
New risk factors (4)
- • hire additional personnel, including clinical, regulatory and scientific employees and consultants;
- Finally, in December 2025, the National Defense Authorization Act for Fiscal Year 2026, or the NDAA, was enacted, which includes Section 851, commonly referred to as the "BIOSECURE Act." Once the BIOSECURE Act's prohibitions take effect, U.S. government agencies will not be permitted to procure biotechnology…
- GDPR may result in warning letters, mandatory audits, orders to cease/change the use of data, and financial penalties, including fines, which can be up to 4% of global revenues or €20 million (£17.5 million for the U.K.), whichever is greater. The GDPR also confers a private right of action on data subjects and…
- dollars. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the euro. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial…
Removed risk factors (2)
- Finally, in December 2025, the National Defense Authorization Act for Fiscal Year 2026, or the NDAA, was enacted, which includes Section 851, commonly referred to as the "BIOSECURE Act." The BIOSECURE Act restricts U.S. government agencies from procuring biotechnology equipment or services from, or entering into…
- SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.
New legal mentions (1)
- As of September 30, 2026, we were not a party to any material legal proceedings.